A ARTIVION INC
$34.17
| Market Cap | $1.64B |
| P/E Ratio | 162.71 |
| Forward P/E | 29.56 |
| Dividend Yield | — |
| Beta | 1.62 |
| 52W Range | $22.19 - $47.63 |
| # Hedge Funds | 2 |
| Sector | Healthcare |
| Industry | Medical Devices |
Hedge Fund Ownership
| Investor 2 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| First Eagle Investment Management First Eagle Investment Management | 0.02% | $14.00M | 306,893 | Reduce 9.84% |
| Polen Capital Management Polen Capital Management | 0.00% | $1.15M | 25,259 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 79 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Holloway Jean FSVP, General Counsel | Sale | 8,962 | $38.00 | $340.56K | 04 Mar 2026 | 04 Mar 2026 |
| Holloway Jean FSVP, General Counsel | Sale | 3,843 | $37.78 | $145.17K | 03 Mar 2026 | 04 Mar 2026 |
| Davis John EChief Commercial Officer | Sale | 4,573 | $37.78 | $172.75K | 03 Mar 2026 | 04 Mar 2026 |
| Horton AmyVP, Chief Accounting Officer | Sale | 901 | $37.78 | $34.04K | 03 Mar 2026 | 04 Mar 2026 |
| Berry Lance AEVP, COO, CFO & Treasurer | Sale | 6,316 | $37.78 | $238.59K | 03 Mar 2026 | 04 Mar 2026 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 2,149 | $37.78 | $81.18K | 03 Mar 2026 | 04 Mar 2026 |
| Mackin James PPresident & CEO | Sale | 17,887 | $37.78 | $675.69K | 03 Mar 2026 | 04 Mar 2026 |
| Holloway Jean FSVP, General Counsel | Sale | 2,183 | $38.02 | $83.01K | 02 Mar 2026 | 03 Mar 2026 |
| Berry Lance AEVP, COO, CFO & Treasurer | Sale | 5,178 | $38.02 | $196.89K | 02 Mar 2026 | 03 Mar 2026 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 1,513 | $38.02 | $57.53K | 02 Mar 2026 | 03 Mar 2026 |
| Horton AmyVP, Chief Accounting Officer | Sale | 641 | $38.02 | $24.37K | 02 Mar 2026 | 03 Mar 2026 |
| Mackin James PPresident & CEO | Sale | 14,911 | $38.02 | $566.99K | 02 Mar 2026 | 03 Mar 2026 |
| Davis John EChief Commercial Officer | Sale | 2,784 | $38.02 | $105.86K | 02 Mar 2026 | 03 Mar 2026 |
| Amy HortonVP, Chief Accounting Officer | Sale | 830 | $35.69 | $29.63K | 24 Feb 2026 | 25 Feb 2026 |
| Lance A BerryEVP, COO, CFO & Treasurer | Sale | 4,485 | $35.69 | $160.08K | 24 Feb 2026 | 25 Feb 2026 |
| Marshall S. StantonSVP, Clinical & MD Affair | Sale | 1,259 | $35.69 | $44.94K | 24 Feb 2026 | 25 Feb 2026 |
| Jean F HollowaySVP, General Counsel | Sale | 1,668 | $35.69 | $59.54K | 24 Feb 2026 | 25 Feb 2026 |
| James P MackinPresident & CEO | Sale | 13,936 | $35.69 | $497.42K | 24 Feb 2026 | 25 Feb 2026 |
| John E DavisChief Commercial Officer | Sale | 2,075 | $35.69 | $74.06K | 24 Feb 2026 | 25 Feb 2026 |
| Berry Lance AEVP, COO, CFO & Treasurer | Sale | 4,485 | $35.69 | $160.08K | 24 Feb 2026 | 25 Feb 2026 |
| Horton AmyVP, Chief Accounting Officer | Sale | 830 | $35.69 | $29.63K | 24 Feb 2026 | 25 Feb 2026 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 1,259 | $35.69 | $44.94K | 24 Feb 2026 | 25 Feb 2026 |
| Holloway Jean FSVP, General Counsel | Sale | 1,668 | $35.69 | $59.54K | 24 Feb 2026 | 25 Feb 2026 |
| Davis John EChief Commercial Officer | Sale | 2,075 | $35.69 | $74.06K | 24 Feb 2026 | 25 Feb 2026 |
| Mackin James PPresident & CEO | Sale | 13,936 | $35.69 | $497.42K | 24 Feb 2026 | 25 Feb 2026 |
| Amy HortonVP, Chief Accounting Officer | Sale | 1,731 | $37.59 | $65.06K | 23 Feb 2026 | 25 Feb 2026 |
| Marshall S. StantonSVP, Clinical & MD Affair | Sale | 2,423 | $37.59 | $91.08K | 23 Feb 2026 | 25 Feb 2026 |
| Jean F HollowaySVP, General Counsel | Sale | 3,079 | $37.59 | $115.73K | 23 Feb 2026 | 25 Feb 2026 |
| James P MackinPresident & CEO | Sale | 20,962 | $37.59 | $787.92K | 23 Feb 2026 | 25 Feb 2026 |
| Lance A BerryEVP, COO, CFO & Treasurer | Sale | 4,981 | $37.59 | $187.23K | 23 Feb 2026 | 25 Feb 2026 |
| John E DavisChief Commercial Officer | Sale | 3,773 | $37.59 | $141.82K | 23 Feb 2026 | 25 Feb 2026 |
| Berry Lance AEVP, COO, CFO & Treasurer | Sale | 4,981 | $37.59 | $187.23K | 23 Feb 2026 | 25 Feb 2026 |
| Horton AmyVP, Chief Accounting Officer | Sale | 1,731 | $37.59 | $65.06K | 23 Feb 2026 | 25 Feb 2026 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 2,423 | $37.59 | $91.08K | 23 Feb 2026 | 25 Feb 2026 |
| Holloway Jean FSVP, General Counsel | Sale | 3,079 | $37.59 | $115.73K | 23 Feb 2026 | 25 Feb 2026 |
| Davis John EChief Commercial Officer | Sale | 3,773 | $37.59 | $141.82K | 23 Feb 2026 | 25 Feb 2026 |
| Mackin James PPresident & CEO | Sale | 20,962 | $37.59 | $787.92K | 23 Feb 2026 | 25 Feb 2026 |
| Davis John EChief Commercial Officer | Sale | 5,000 | $45.11 | $225.55K | 15 Dec 2025 | 17 Dec 2025 |
| Horton AmyVP, Chief Accounting Officer | Sale | 4,572 | $44.42 | $203.08K | 08 Dec 2025 | 09 Dec 2025 |
| Mackin James PPresident & CEO | Sale | 30,921 | $45.46 | $1.41M | 03 Dec 2025 | 04 Dec 2025 |
| Holloway Jean FSVP, General Counsel | Sale | 5,267 | $45.30 | $238.60K | 03 Dec 2025 | 04 Dec 2025 |
| Holloway Jean FSVP, General Counsel | Sale | 2,048 | $45.30 | $92.77K | 03 Dec 2025 | 04 Dec 2025 |
| Jean F HollowaySVP, General Counsel | Sale | 5,267 | $45.30 | $238.60K | 03 Dec 2025 | 04 Dec 2025 |
| James P MackinPresident & CEO | Sale | 30,921 | $45.46 | $1.41M | 03 Dec 2025 | 04 Dec 2025 |
| Jean F HollowaySVP, General Counsel | Sale | 2,048 | $45.30 | $92.77K | 03 Dec 2025 | 04 Dec 2025 |
| Mackin James PPresident & CEO | Sale | 30,921 | $45.56 | $1.41M | 02 Dec 2025 | 03 Dec 2025 |
| James P MackinPresident & CEO | Sale | 30,921 | $45.56 | $1.41M | 02 Dec 2025 | 03 Dec 2025 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 18,705 | $44.91 | $840.04K | 21 Nov 2025 | 24 Nov 2025 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 14,586 | $44.92 | $655.19K | 21 Nov 2025 | 24 Nov 2025 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 8,370 | $45.35 | $379.54K | 21 Nov 2025 | 24 Nov 2025 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 5,715 | $45.35 | $259.15K | 21 Nov 2025 | 24 Nov 2025 |
| Marshall S. StantonSVP, Clinical & MD Affair | Sale | 8,370 | $45.35 | $379.54K | 21 Nov 2025 | 24 Nov 2025 |
| Marshall S. StantonSVP, Clinical & MD Affair | Sale | 18,705 | $44.91 | $840.04K | 21 Nov 2025 | 24 Nov 2025 |
| Marshall S. StantonSVP, Clinical & MD Affair | Sale | 5,715 | $45.35 | $259.15K | 21 Nov 2025 | 24 Nov 2025 |
| Marshall S. StantonSVP, Clinical & MD Affair | Sale | 14,586 | $44.92 | $655.19K | 21 Nov 2025 | 24 Nov 2025 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 1,355 | $44.28 | $60.00K | 20 Nov 2025 | 24 Nov 2025 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 2,033 | $44.32 | $90.09K | 20 Nov 2025 | 24 Nov 2025 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 11,888 | $44.14 | $524.74K | 20 Nov 2025 | 24 Nov 2025 |
| Marshall S. StantonSVP, Clinical & MD Affair | Sale | 1,355 | $44.28 | $60.00K | 20 Nov 2025 | 24 Nov 2025 |
| Marshall S. StantonSVP, Clinical & MD Affair | Sale | 2,033 | $44.32 | $90.09K | 20 Nov 2025 | 24 Nov 2025 |
| Marshall S. StantonSVP, Clinical & MD Affair | Sale | 11,888 | $44.14 | $524.74K | 20 Nov 2025 | 24 Nov 2025 |
| Hoff Elizabeth A | Sale | 4,200 | $45.10 | $189.41K | 18 Nov 2025 | 19 Nov 2025 |
| Elizabeth A HoffDirector | Sale | 4,200 | $45.10 | $189.41K | 18 Nov 2025 | 19 Nov 2025 |
| Horton AmyVP, Chief Accounting Officer | Sale | 6,000 | $45.73 | $274.38K | 17 Nov 2025 | 18 Nov 2025 |
| Holloway Jean FSVP, General Counsel | Sale | 6,394 | $45.17 | $288.82K | 17 Nov 2025 | 18 Nov 2025 |
| Davis John EChief Commercial Officer | Sale | 6,394 | $45.17 | $288.82K | 17 Nov 2025 | 18 Nov 2025 |
| Holloway Jean FSVP, General Counsel | Sale | 6,393 | $45.00 | $287.69K | 14 Nov 2025 | 18 Nov 2025 |
| Davis John EChief Commercial Officer | Sale | 6,393 | $44.67 | $285.58K | 14 Nov 2025 | 18 Nov 2025 |
| Mackin James PPresident & CEO | Sale | 34,210 | $45.86 | $1.57M | 13 Nov 2025 | 14 Nov 2025 |
| Horton AmyVP, Chief Accounting Officer | Sale | 3,482 | $45.86 | $159.68K | 13 Nov 2025 | 14 Nov 2025 |
| Holloway Jean FSVP, General Counsel | Sale | 5,761 | $45.86 | $264.19K | 13 Nov 2025 | 14 Nov 2025 |
| Davis John EChief Commercial Officer | Sale | 6,563 | $45.86 | $300.97K | 13 Nov 2025 | 14 Nov 2025 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 4,993 | $45.86 | $228.97K | 13 Nov 2025 | 14 Nov 2025 |
| Holloway Jean FSVP, General Counsel | Sale | 10,000 | $46.18 | $461.80K | 11 Nov 2025 | 12 Nov 2025 |
| Davis John EChief Commercial Officer | Sale | 3,373 | $44.62 | $150.50K | 10 Nov 2025 | 12 Nov 2025 |
| Holloway Jean FSVP, General Counsel | Sale | 2,960 | $44.62 | $132.07K | 10 Nov 2025 | 12 Nov 2025 |
| Horton AmyVP, Chief Accounting Officer | Sale | 1,789 | $44.62 | $79.82K | 10 Nov 2025 | 12 Nov 2025 |
| Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 2,566 | $44.62 | $114.49K | 10 Nov 2025 | 12 Nov 2025 |
| Mackin James PPresident & CEO | Sale | 17,580 | $44.62 | $784.40K | 10 Nov 2025 | 12 Nov 2025 |
Frequently Asked Questions
What is AORT stock price today?
ARTIVION INC (AORT) is currently trading at $34.17. The stock has a 52-week range of $22.19 to $47.63 and a market capitalization of $1.64B.
Is AORT a good stock to buy in 2026?
ARTIVION INC has a P/E ratio of 162.7 (forward P/E: 29.6), a dividend yield of none, and 1-year performance of +41.5%. 2 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling AORT stock?
There have been 79 insider transactions for AORT in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has AORT stock performed over the past year?
ARTIVION INC (AORT) has returned +41.5% over the past 12 months. The stock traded between $22.19 and $47.63 during this period, and is currently at $34.17.
Which hedge funds own AORT (ARTIVION INC)?
2 tracked hedge funds currently hold AORT in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is AORT's market cap and valuation?
ARTIVION INC (AORT) has a market capitalization of $1.64B. The trailing P/E ratio is 162.7 and forward P/E is 29.6. The stock is classified in the Healthcare sector.
What is AORT's revenue and profitability?
ARTIVION INC reported revenue of $441.33M with net income of $9.76M and a profit margin of 0.02%. The stock has a beta of 1.62.
What sector is AORT in and who are its biggest institutional holders?
ARTIVION INC (AORT) operates in the Healthcare sector. It is held by 2 tracked hedge funds. See the ownership table above for the complete list.